-
Product Insights
NewATP Binding Cassette Sub Family A Member 1 – Drugs In Development, 2024
The ATP Binding Cassette Sub Family A Member 1 pipeline drugs market research report outlays comprehensive information on the ATP Binding Cassette Sub Family A Member 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Cardiovascular, Gastrointestinal, Metabolic Disorders, and Genito Urinary System which include indications of Atherosclerosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Type 1 Diabetes...
-
Product Insights
NewATP Binding Cassette Sub Family C Member 8 – Drugs In Development, 2024
The ATP Binding Cassette Sub Family C Member 8 pipeline drugs market research report outlays comprehensive information on the ATP Binding Cassette Sub Family C Member 8 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Metabolic Disorders, and Central Nervous System which include indications of Type 2 Diabetes, Gestational Diabetes, and Central Nerve Injury. It also reviews...
-
Product Insights
NewATP Binding Cassette Sub Family G Member 2 – Drugs In Development, 2024
The ATP Binding Cassette Sub Family G Member 2 pipeline drugs market research report outlays comprehensive information on the ATP Binding Cassette Sub Family G Member 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Unspecified Cancer, and Triple-Negative Breast Cancer (TNBC). It also reviews key players involved in ATP Binding Cassette...
-
Product Insights
NewEukaryotic Peptide Chain Release Factor GTP Binding Subunit ERF3A – Drugs In Development, 2024
The Eukaryotic Peptide Chain Release Factor GTP Binding Subunit ERF3A pipeline drugs market research report outlays comprehensive information on the Eukaryotic Peptide Chain Release Factor GTP Binding Subunit ERF3A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Unspecified Cancer, and Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). It also reviews key players...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLYB-116 in Myasthenia Gravis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLYB-116 in Myasthenia Gravis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLYB-116 in Myasthenia Gravis Drug Details: RLYB-116 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imneskibart in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imneskibart in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imneskibart in Colorectal Cancer Drug Details: imneskibart (AU-007) is development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imneskibart in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imneskibart in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imneskibart in Melanoma Drug Details: imneskibart (AU-007) is development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imneskibart in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imneskibart in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imneskibart in Pancreatic Cancer Drug Details: imneskibart (AU-007) is development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imneskibart in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imneskibart in Bladder Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imneskibart in Bladder Cancer Drug Details: imneskibart (AU-007) is development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Imneskibart in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Imneskibart in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imneskibart in Solid Tumor Drug Details: imneskibart (AU-007) is development for...